Adenoviral Vectors for Gene Therapy Research
Adenoviral vectors (AdVs) are highly efficient, non-integrating viral vectors widely used for transient, high-level gene expression in both dividing and non-dividing cells. Known for their broad tropism and large cloning capacity (up to 30 kb for helper-dependent vectors), AdVs are ideal for gene therapy, oncolytic virotherapy, and vaccine development. At Creative Biolabs, we offer a comprehensive suite of customized adenoviral vector services. Our optimized platforms ensure maximum efficiency, robust safety profiles, and scalability, providing reliable support from initial design to rigorous quality control.
High Efficiency & Tropism
Capable of infecting a wide variety of cell types with nearly 100% transduction efficiency without requiring cell division.
Non-integrating Safety
Remains episomal in the host nucleus, eliminating the risk of insertional mutagenesis associated with integrating vectors.
Large Cargo Capacity
Accommodates up to 7.5 kb in standard E1/E3 deleted vectors, and up to 30 kb in helper-dependent (gutless) vectors.
Vector Construction Services
We provide highly customized and specialized adenoviral vector construction strategies tailored to specific research and therapeutic goals.
Recombinant Adenovirus Rescue in Mammalian Cells
Generate stable, high-yield recombinant adenoviruses utilizing optimized homologous recombination in specialized mammalian cell lines.
Recombinant Adenovirus Construction in Bacterial Systems
Efficient creation of full-length viral plasmids through bacterial artificial chromosomes (BAC) and AdEasy-like systems.
Capsid-modified Adenovirus Vector Construction
Engineer hexon, penton base, or fiber structures to precisely retarget vectors and overcome pre-existing immunity.
Regulated Adenovirus Vector Construction
Gain spatial and temporal control over transgene expression using tightly regulated promoter systems.
Adenovirus Vector Design for Invading Immune System
Implement advanced immune-evasion strategies to minimize host clearance and extend the half-life of your adenoviral vectors.
Pseudotyping Adenoviral Vectors Construction
Create chimeric vectors by swapping fiber knob domains (e.g., Ad5/35) to dramatically alter and optimize cellular infection profiles.
Adenoviral/Retroviral Hybrid Vector Construction
Combine AdV high-capacity delivery with stable retroviral integration capabilities for lasting genomic modification.
Ad/AAV Hybrid Vectors Construction
Leverage adenoviral transport alongside AAV rep/ITR elements for targeted, site-specific integration or sustained maintenance.
Comprehensive Adenoviral Vector Services
Beyond vector construction, we provide end-to-end downstream solutions including high-titer virus packaging, rigorous purification, and multi-faceted quality control, ensuring your adenoviral vectors are immediately ready for demanding preclinical applications.
Virus Packaging & Amplification
We employ robust, scalable protocols to rapidly package engineered viral genomes into functional particles and scale them to meet your specific yield requirements.
Utilization of highly permissive packaging cell lines (such as HEK293 and its derivatives) to trans-complement deleted E1 elements, ensuring highly efficient virus rescue.
From small-scale multi-well formats for library screening to large-scale bioreactor amplification (up to >10¹³ VP), providing flexible yields for both in vitro assays and extensive in vivo animal models.
Purification Technologies
High-purity adenoviral vectors are critical to minimizing cytotoxicity and off-target immune responses. We utilize industry gold-standard techniques to deliver ultra-pure preparations.
Double cesium chloride (CsCl) gradient ultracentrifugation is applied to rigorously separate full, infectious viral particles from empty capsids, defective particles, and host cell debris.
Extensive dialysis or gel filtration to remove CsCl, followed by formulation in optimal storage buffers (e.g., glycerol or sucrose-based buffers) to preserve maximal infectivity during freeze-thaw cycles.
Quality Control (QC)
Every adenoviral batch undergoes strict multi-parameter quality assurance to guarantee safety, identity, and reliability.
Rigorous screening for Replication-Competent Adenovirus (RCA) using cell-based assays, ensuring complete biosafety for all first-generation and helper-dependent vectors.
Routine endotoxin testing (LAL assay) and bioburden/sterility confirmation to ensure the viral vectors are perfectly safe for sensitive in vivo applications.
Titration & Analytics
Accurate quantification is essential for establishing reliable Multiplicity of Infection (MOI) and standardizing your experiments.
Determined via OD260 spectrophotometry or precise quantitative PCR (qPCR) measuring total viral genome copies present in the preparation.
Assessed through classical Plaque Forming Unit (PFU) assays or Tissue Culture Infectious Dose 50 (TCID50) assays to accurately reflect the functional biological activity of the vector.
Risk Control & Safety
Our vector design protocols place maximum emphasis on addressing potential biosafety and cytotoxicity concerns.
E1/E3 Deletion
By removing the E1 gene, the virus is rendered replication-incompetent, making it safe for handling at BSL-2 facilities and preventing unauthorized proliferation in vivo.
RCA Assays
Stringent assays detect and eliminate Replication-Competent Adenovirus (RCA) that can arise from homologous recombination during packaging.
Endotoxin Limits
Stringent purification guarantees endotoxin levels well below thresholds required for in vivo physiological relevance and animal welfare.
Representative Performance Metrics
Our adenoviral vectors are manufactured under stringent quality control. The following ranges represent typical performance observed across numerous projects; actual results may vary based on construct and target cells.
Transduction Efficiency
We typically achieve nearly 100% transduction efficiency in a broad spectrum of dividing and non-dividing mammalian cells, even at relatively low MOIs. Modified capsids ensure high infection rates in CAR-negative cell lines.
Expression Profile
Adenoviral vectors provide a rapid onset of gene expression, usually peaking between 24 to 72 hours post-transduction. Expression remains intensely high transiently (1-4 weeks), making them optimal for fast functional readouts and vaccine development.
Batch-to-Batch Consistency
Our standardized and validated packaging protocols ensure functional titer variation <20% between distinct production runs. Strict CsCl ultracentrifugation guarantees highly concentrated pure virus lots.
Safety Testing
Every lot undergoes rigorous multi-tier testing. We guarantee RCA detection limits below 1 in 10⁹ viral particles. Endotoxin levels are maintained <1 EU/mL to ensure suitability for delicate primary cells and downstream in vivo protocols.
In Vivo Performance
In preclinical animal models, systemic administration (e.g., intravenous) predominantly drives rapid, massive gene expression in the liver. Alternatively, intratumoral or localized injections yield strong localized expression with minimal off-target spread.
Research Applications
Due to their broad tropism and massive expression capacity, our adenoviral vectors support diverse areas of virotherapy and gene transfer research.
Vaccine Development
Delivery of pathogenic antigens or immunomodulators to stimulate robust T-cell and B-cell immune responses in host models.
Oncolytic Virotherapy
Engineered replication-competent (or specifically targeted) vectors designed to selectively lyse tumor cells and stimulate anti-tumor immunity.
Gene Overexpression
Achieve extremely high-level transient expression of therapeutic genes, large transcription factors, or multi-gene cassettes.
CRISPR Gene Editing
Transient delivery of Cas9 and gRNAs is optimal to minimize off-target effects while maintaining high editing efficiency before the vector clears.
Gene Knockdown
Delivery of shRNA or miRNA expression cassettes for rapid and robust silencing of target genes in vitro and in vivo.
In Vivo Delivery
High-capacity vectors ideal for systemic or localized tissue-targeted injection in demanding preclinical animal models.
Why Choose Adenoviral Vectors?
Compare AdV with other prevalent viral systems to determine the best fit for your therapeutic strategy.
| Vector | Integration | Max Cargo | Expression Profile | Best Use Case |
|---|---|---|---|---|
|
Adenovirus
|
Episomal | ~7.5 kb (up to 30 kb) | Fast onset, high transient peak | Vaccines, Oncolytic therapies, high-yield transient models |
| Lentivirus | Integrating | ~8 kb | Stable, long-term | Stable cell lines, ex vivo gene editing |
| AAV | Mostly Episomal | ~4.7 kb | Slower onset, sustained | In vivo gene replacement, low immunogenicity needs |
Service Workflow
Clear and efficient milestones ensure project transparency.
Strategy & Design
Project evaluation and selection of optimal capsid, promoter, and helper system (bacterial or mammalian).
Plasmid Construction
Subcloning of Gene of Interest into the shuttle vector followed by recombination with the adenoviral backbone.
Virus Rescue & Amplification
Transfection into packaging cell lines (e.g., HEK293) and subsequent scale-up based on project requirements.
Purification & QC
CsCl gradient ultracentrifugation, dialysis, precise titer measurement (PFU/mL), and RCA negative verification.
Delivery
Aliquoted virus stored at -80°C shipped on dry ice alongside comprehensive technical reports.
What You Receive
All essential materials properly documented and ready for your experiments.
Transfer Plasmid
Sequence-verified shuttle plasmid containing your gene of interest, along with glycerol stocks and full vector mapping.
High-Titer Virus
Purified recombinant adenovirus (typically 10¹⁰ - 10¹² PFU/mL) carefully aliquoted in optimal storage buffers.
QC Report
Comprehensive Certificate of Analysis (CoA) including physical titer (VP), infectious titer (PFU), RCA testing, and sterility results.
Published Data
Gene Editing and Cancer Immunotherapy: The Nemesis of Tumor Immune Escape
Background
While PD-L1 antibodies target surface proteins, tumor cells often circumvent this blockade by redistributing intracellular PD-L1 to the membrane, thereby sustaining immune resistance. To overcome this adaptive homeostasis, there is an urgent need for alternatives that permanently abolish PD-L1 expression. Moving beyond simple surface inhibition to total genomic or proteomic silencing could significantly improve clinical outcomes in ICB therapy.
Solution
This research introduces an innovative gene therapy approach by loading CRISPR/Cas9 components into an adenoviral vector (sgCas9-AdV) and encapsulating the vector within a Silk-Gel hydrogel. The hydrogel acts as a protective reservoir, enabling sustained release of the vector for 9 days while shielding it from host immune clearance. By achieving a PD-L1 knockout efficiency of up to 78.7%, the system significantly suppressed tumor growth in various models, including Hepa 1-6 liver cancer and CT26 colon cancer.
Result
Unlike traditional anti-PD-L1 antibody treatments that require frequent administration, this localized gene-editing system induced a durable, T-cell-mediated anti-tumor response. The study highlights the breakthrough potential of adenoviral vectors in precise genome editing, transforming them into powerful tools for "curative" cancer immunotherapy across multiple solid tumor types.
Figure 1. The silk‐gel protects sgCas9‐AdV from antibody neutralization by the host and enables their sustained release to improve gene editing efficiency and therapeutic efficacy.
Wu M, Li H, Zhang C, et al. Silk‐Gel Powered Adenoviral Vector Enables Robust Genome Editing of PD‐L1 to Augment Immunotherapy across Multiple Tumor Models. Advanced Science, 2023, 10(12): 2206399. 10.1002/advs.202206399 Distributed under Open Access license CC BY 4.0, without modification.
Frequently Asked Questions
Start Your AdV Project
Outline your parameters for an accurate feasibility assessment:
- Insert Size: Is your payload compatible with standard E1/E3 deletion or do you need a gutless vector?
- Tropism Requirements: Do you need Ad5, Ad35, or a specifically pseudotyped fiber?
- In vivo / In vitro: Establishes purification stringency and target titer.
- Scale: Required total PFU/VP.
Get a Custom Quote
Our virology specialists are ready to tailor an adenoviral system to your precise needs.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
